Lu Hongbo

Director Lu Hongbo buys 3,768 shares at $18.63; stock down 50.3% from 52-week high amid unprofitability ($-51.5M net income).

Lu Hongbo purchased 3,768 shares at $18.63 on 2026-03-31, increasing his holdings to 426,736 shares. The transaction occurs as Zenas BioPharma trades at $21.46, substantially below its 52-week high of $43.17 and down 14.8% over the past 30 days and 37.8% over 90 days. The company remains unprofitable with a net income of $-51,499,000.00 despite 100% annual revenue growth. Prior to this purchase, Lu's cross-ticker track record shows an average 90-day return of -25.8% across 10 buys, with a 0.00% win rate, while his same-ticker history at ZBIO shows 0 of 3 prior buys were well-timed at the 90-day mark. A cluster buy pattern has emerged, with 2 other insiders also purchasing within the past 14 days, though this does not establish coordination across individuals.

Director Lu Hongbo bought 75,000 shares of ZBIO at $20.00 on 2026-03-31 ($1.5M); stock now at $19.55, down 46.2% over 90 days.

Lu Hongbo purchased 75,000 shares at $20.00, increasing his holdings by 21.6% from 348.0K to 423.0K shares. The purchase occurred as ZBIO trades 54.7% below its 52-week high and has declined 46.2% over the past 90 days. His prior 4 measurable same-ticker buys at ZBIO show a 0% win rate at the 90-day mark, with three of them followed by significant declines. The company is unprofitable with -$51.5M net income in its most recent fiscal year, generating zero revenue in the latest quarter, though it reports 100.0% annual revenue growth year-over-year. A cluster pattern exists, with 2 other insiders also purchasing within the past 14 days. The purchase combination—substantial position increase into momentum weakness, prior poor timing outcomes, and aggregate insider buying amid unprofitability—suggests this trade merits investor scrutiny of ZBIO's strategic position.

Director Lu Hongbo purchases 25,985 shares of ZBIO at $22.50 on 2026-02-11; company posted -$51.5M net income with -90.0% revenue decline.

Lu Hongbo acquired 25,985 shares at $22.50, increasing his stake by 8.1% to 348.0K shares total in a biotech company reporting severe operating losses of -$51.5M and annual revenue decline of -90.0%. The purchase occurred within a 14-day cluster window alongside 2 other insider buys, suggesting coordinated board or management interest despite deteriorating fundamentals. His prior three trades at ZBIO show a poor 90-day timing record: none were well-timed, with two producing -45.6% returns and one -12.6%. The stock is currently 38.8% below its 52-week high, though up 17.0% over 30 days, presenting a conflicting signal of near-term momentum against a backdrop of substantial fiscal deterioration and historically unfavorable trade timing by this insider at this specific ticker.

Director Lu Hongbo purchases 322.0K shares at $18.63 avg in 2 transactions totaling $6.0M as stock hits 52-week high

Lu Hongbo, a Director, executed 2 separate open-market purchases totaling 322.0K shares for $6,000,031.00, with a blended average price of $18.63. The second purchase of 263,160 shares at $19.00 occurred as the stock reached its 52-week high of $27.76 (currently +0.0% from that high), representing a significant accumulation by a board member. However, this buy activity occurs within a fundamentally challenged company: Zenas BioPharma reported $0.00 revenue in the latest quarter, a $-52,223,000.00 net loss, and -90.0% annual revenue decline, while maintaining only $1.2B market cap. The insider's cross-ticker track record shows 6 prior buys with a 0% win rate at the 90-day mark (avg 90d return -24.8%), and his one prior ZBIO purchase on the same date (2024-09-13) subsequently declined -45.6% over 90 days, establishing a pattern of poor timing on this specific stock. A cluster of 5 other insiders also bought within 14 days, though this does not mitigate the fundamental deterioration and the director's demonstrated inability to execute well-timed purchases at this ticker.

Director Lu Hongbo buys 476,190 shares at $10.50 for $4,999,995.00 amid unprofitable operations and negative track record

Lu Hongbo, a director at Terns Pharmaceuticals, executed 2 separate purchases totaling 476,190 shares for $4,999,995.00 at $10.50 per share on 2024-09-12, bringing his holding from zero to 476,190 shares. The transaction represents a substantial absolute commitment ($5.0M), but occurs against concerning context: the company reported net income of $-22,736,000.00 and annual revenue growth of -100.0%, signaling material operational distress. Compounding this, Lu's cross-ticker insider trading track record shows 5 prior buys with a 90-day win rate of 0.00% and average 90-day return of -10.2%, indicating a history of purchases that subsequently underperformed. The stock is currently trading at $9.63, down 14.2% from its 52-week high despite a 30-day rally of +32.8%, suggesting recent price momentum that may have prompted this entry—but without conviction signal from the insider's historical outcomes.

Director Lu Hongbo buys 58.8K shares of ZBIO at $17.00 ($999,991 total); 5 other insiders also bought in past 14 days.

Lu Hongbo, a director at Zenas BioPharma, purchased 58,823 shares at $17.00 for a total value of $999,991.00, establishing an initial position in the company just 3 trading days after its recent listing. This transaction is notable not in isolation but as part of a broader pattern: 5 other insiders have made purchases within the same 14-day window, indicating multiple members of the leadership team are acquiring shares shortly after going public. Early insider accumulation during the IPO aftermarket period often reflects confidence in the company's trajectory, though this pattern is not yet fully informative given ZBIO's recent listing status—52-week comparisons and longer-term valuation context are not yet available. Investors should track whether this cluster-buy pattern persists and monitor subsequent insider activity to assess the consistency of insider positioning.